Teachers Retirement System of The State of Kentucky held its stake in shares of Meridian Bioscience Inc. (NASDAQ:VIVO) during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 17,150 shares of the company’s stock at the end of the first quarter. Teachers Retirement System of The State of Kentucky’s holdings in Meridian Bioscience were worth $237,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Barrow Hanley Mewhinney & Strauss LLC bought a new stake in shares of Meridian Bioscience during the first quarter valued at $105,000. BNP Paribas Arbitrage SA boosted its stake in shares of Meridian Bioscience by 12.5% in the first quarter. BNP Paribas Arbitrage SA now owns 8,633 shares of the company’s stock valued at $119,000 after buying an additional 960 shares in the last quarter. Mason Street Advisors LLC boosted its stake in shares of Meridian Bioscience by 7.2% in the first quarter. Mason Street Advisors LLC now owns 9,868 shares of the company’s stock valued at $136,000 after buying an additional 667 shares in the last quarter. OppenheimerFunds Inc. bought a new stake in shares of Meridian Bioscience during the first quarter valued at $161,000. Finally, Koch Industries Inc. bought a new stake in shares of Meridian Bioscience during the first quarter valued at $165,000. Hedge funds and other institutional investors own 85.83% of the company’s stock.
Meridian Bioscience Inc. (NASDAQ VIVO) traded up 2.60% on Friday, hitting $13.80. 72,380 shares of the company traded hands. The firm has a market capitalization of $582.39 million, a PE ratio of 27.60 and a beta of 0.89. Meridian Bioscience Inc. has a 1-year low of $10.75 and a 1-year high of $19.85. The firm’s 50 day moving average price is $14.88 and its 200 day moving average price is $14.01.
Meridian Bioscience (NASDAQ:VIVO) last issued its earnings results on Thursday, July 27th. The company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. The company had revenue of $50.14 million for the quarter, compared to the consensus estimate of $49.13 million. Meridian Bioscience had a return on equity of 16.93% and a net margin of 10.77%. The firm’s quarterly revenue was down 1.0% on a year-over-year basis. During the same quarter last year, the company earned $0.21 EPS. Equities research analysts predict that Meridian Bioscience Inc. will post $0.67 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 17th. Investors of record on Monday, August 7th will be paid a dividend of $0.125 per share. This represents a $0.50 annualized dividend and a yield of 3.72%. The ex-dividend date is Thursday, August 3rd. Meridian Bioscience’s dividend payout ratio (DPR) is presently 98.04%.
TRADEMARK VIOLATION WARNING: This article was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.com-unik.info/2017/08/11/meridian-bioscience-inc-vivo-position-maintained-by-teachers-retirement-system-of-the-state-of-kentucky.html.
Several brokerages have recently weighed in on VIVO. BidaskClub cut Meridian Bioscience from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Zacks Investment Research cut Meridian Bioscience from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Canaccord Genuity upped their price target on Meridian Bioscience from $13.00 to $15.00 and gave the company a “hold” rating in a research report on Wednesday, May 3rd. Three research analysts have rated the stock with a sell rating and four have given a hold rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $14.75.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
What are top analysts saying about Meridian Bioscience Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Meridian Bioscience Inc. and related companies.